What's in Astellas Pharma China, Inc.'s pipeline?

Astellas Pharma China, Inc. has 10 drugs in our index: 5 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Astellas Pharma China, Inc.'s portfolio?

Top competitors by shared drug class: Nanfang Hospital, Southern Medical University, Assistance Publique - Hôpitaux de Paris, Al-Azhar University, Hospices Civils de Lyon, Peking University People's Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/astellas-pharma-china-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Astellas Pharma China, Inc. — Portfolio Competitive Intelligence Brief

Astellas Pharma China, Inc. pipeline: 5 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 2 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Tacrolimus sustained-release capsule	Tacrolimus sustained-release capsule	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)	Immunology
Tacrolimus prolonged-release formulation	Tacrolimus prolonged-release formulation	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)	Immunology
Perdipine injection	Perdipine injection	marketed
Mycophenolic acid drugs	Mycophenolic acid drugs	marketed
Tacrolimus immediate-release formulation	Tacrolimus immediate-release formulation	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)	Immunology
Cyclophosphamide injections	Cyclophosphamide injections	phase 3	Alkylating agent	DNA	Oncology
Plaebo	Plaebo	phase 3			Other

Therapeutic area mix

Immunology · 4
Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Nanfang Hospital, Southern Medical University · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Al-Azhar University · 2 shared drug classes
Hospices Civils de Lyon · 2 shared drug classes
Peking University People's Hospital · 2 shared drug classes
Asahi Kasei Pharma Corporation · 1 shared drug class
Armando Torres Ramírez · 1 shared drug class
Alberta Health services · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Astellas Pharma China, Inc.:

Cite this brief

Drug Landscape (2026). Astellas Pharma China, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/astellas-pharma-china-inc. Accessed 2026-05-16.